Epidemiology and Predictors of Mortality in Cases of Candida Bloodstream Infection: Results from Population-Based Surveillance, Barcelona, Spain, from 2002 to 2003

Abstract

We conducted population-based surveillance for Candida bloodstream infections in Spain to determine its incidence, the extent of antifungal resistance, and risk factors for mortality. A case was defined as the first positive blood culture for any Candida spp. in a resident of Barcelona, from 1 January 2002 to 31 December 2003. We defined early mortality as occurring between days 3 to 7 after candidemia and late mortality as occurring between days 8 to 30. We detected 345 cases of candidemia, for an average annual incidence of 4.3 cases/100,000 population, 0.53 cases/1,000 hospital discharges, and 0.73 cases/10,000 patient-days. Outpatients comprised 11% of the cases, and 89% had a central venous catheter (CVC) at diagnosis. Overall mortality was 44%. Candida albicans was the most frequent species (51% of cases), followed by Candida parapsilosis (23%), Candida tropicalis (10%), Candida glabrata (8%), Candida krusei (4%), and other species (3%). Twenty-four isolates (7%) had decreased susceptibility to fluconazole (MIC > 16 g/ml). On multivariable analysis, early death was independently associated with hematological malignancy (odds ratio [

Candidaemia in a tertiary care academic hospital in Italy. The impact of C. parapsilosis complex on the species distribution and antifungal susceptibility

“…The epidemiology of candidaemia has been studied extensively worldwide, mainly in the United States, Europe and South America [17][18][19][20]. In this paper we reported data concerning BSIs involving Candida spp.…”

Epidemiology of candidaemia in critically ill trauma patients: experiences of a level I trauma centre in North India

“…Higher rates have been reported in developing countries such as Brazil (0.37 per 1000 patient days, 2.49 cases per 1000 admissions) (Colombo et al, 2006) and Taiwan (2.88 per 1000 admissions) (Hsueh et al, 2002) in comparison with developed countries such as the USA (0.46 per 1000 admissions) (Wisplinghoff et al, 2004) and Spain (0.53 episodes per 1000 discharges or 0.73 episodes per 10 000 patient days) (Almirante et al, 2005), where the incidence is much lower. In our study, the incidence of candidaemia was 0.71 episodes per 1000 patient days or 27.6 cases per 1000 admissions.…”

A Randomized, Blinded, Multicenter Trial of Lipid-Associated Amphotericin B Alone versus in Combination with an Antibody-Based Inhibitor of Heat Shock Protein 90 in Patients with Invasive Candidiasis

“…For C. parapsilosis, this rate was 2%. In studies that correlated early deaths (within 7 days of candidemia) with candidiasis, the mortality rates were 21% [28] and 22% [29].…”